ArticleThe journal of headache and pain2025
Acute headache treatment in idiopathic intracranial hypertension: treating to the phenotype?
Article in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundEffective acute headache treatment is essential for improving the quality of life in people with idiopathic intracranial hypertension (pwIIH). While current guidance recommends “treat to the phenotype”, robust data on effectiveness of available options is lacking.
methodsThis retrospective analysis used standardized symptom diaries of pwIIH from the Vienna Idiopathic Intracranial Hypertension (VIIH) database (1-JUL-2021 to 30-JUN-2023). Three classes of acute medications (nonsteroidal anti-inflammatory drugs [NSAID], acetaminophen [APAP], and triptans) were analyzed, with NSAIDs as the reference. Headache attacks were classified per ICHD-3 as migraine (MIG), tension-type (TTH), or other (OTH). We used 2-level nested logistic regression models to analyze odds ratio (OR) of treatment response for each headache type, adjusting for covariance within individual pwIIH and concurrent medication with propensity-weighting for age, sex, and headache severity.
resultsWe analyzed 35,640 medication-outcome pairs from 23,507 headache attacks (45.3% MIG, 21.1% TTH, 33.6% OTH) in 156 patients (89.7% female, mean age 32.9 years). NSAID were most commonly used across all headache types (MIG: 60.5%, TTH: 69.8%, OTH: 70.7%), followed by APAP (MIG: 21.5%, TTH: 21.1%, OTH: 27.7%) and triptans (MIG: 18%, TTH: 10.1%, OTH: 12.8%). Triptans were the most effective across all headache types (OR for MIG: 4.8 [CI 3.9–6.1], TTH: 2.9 [CI 1.8–4.3], OTH: 3.1 [CI 2.2–4.3]). APAP was less effective for MIG (OR 0.81 [CI 0.74–0.90]) but similar to NSAIDs in TTH and OTH.
conclusionsTriptans are associated with better response rates than NSAID/APAP in acute management of headaches in pwIIH, particularly – but not exclusively – for migraine-type attacks. These findings support preferential use of triptans, questioning the “treating to the phenotype” approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.